BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35256571)

  • 1. Real-world data on melanoma brain metastases and survival outcome.
    Pedersen S; Møller S; Donia M; Persson GF; Svane IM; Ellebaek E
    Melanoma Res; 2022 Jun; 32(3):173-182. PubMed ID: 35256571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review.
    Goyal S; Silk AW; Tian S; Mehnert J; Danish S; Ranjan S; Kaufman HL
    JAMA Oncol; 2015 Aug; 1(5):668-76. PubMed ID: 26181286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
    Dohm AE; Nakashima JY; Kalagotla H; Jiang SX; Tang JD; Bhandari M; Kim Y; Graham JA; Khushalani NI; Forsyth PA; Etame AB; Liu JK; Tran ND; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Ahmed KA
    Eur J Cancer; 2023 Oct; 192():113287. PubMed ID: 37657227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
    Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
    Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
    Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
    Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM
    Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases.
    Jiang C; Kleber TJ; Switchenko JM; Khan MK
    Radiat Oncol; 2021 Feb; 16(1):31. PubMed ID: 33557890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
    Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
    Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases.
    Moyers JT; Chong EG; Peng J; Tsai HHC; Sufficool D; Shavlik D; Nagaraj G
    Cancer Med; 2021 Feb; 10(4):1201-1211. PubMed ID: 33484100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
    Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
    Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
    Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
    Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging options for patients with melanoma brain metastases.
    Kreidieh FY; Tawbi HA
    Clin Adv Hematol Oncol; 2022 Oct; 20(10):619-627. PubMed ID: 36206074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Sloot S; Chen YA; Zhao X; Weber JL; Benedict JJ; Mulé JJ; Smalley KS; Weber JS; Zager JS; Forsyth PA; Sondak VK; Gibney GT
    Cancer; 2018 Jan; 124(2):297-305. PubMed ID: 29023643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma brain metastases - Interdisciplinary management recommendations 2020.
    Gutzmer R; Vordermark D; Hassel JC; Krex D; Wendl C; Schadendorf D; Sickmann T; Rieken S; Pukrop T; Höller C; Eigentler TK; Meier F
    Cancer Treat Rev; 2020 Sep; 89():102083. PubMed ID: 32736188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
    Rauschenberg R; Bruns J; Brütting J; Daubner D; Lohaus F; Zimmer L; Forschner A; Zips D; Hassel JC; Berking C; Kaehler KC; Utikal J; Gutzmer R; Terheyden P; Meiss F; Rafei-Shamsabadi D; Kiecker F; Debus D; Dabrowski E; Arnold A; Garzarolli M; Kuske M; Beissert S; Löck S; Linn J; Troost EGC; Meier F
    Eur J Cancer; 2019 Mar; 110():11-20. PubMed ID: 30739835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis.
    Amaral T; Tampouri I; Eigentler T; Keim U; Klumpp B; Heinrich V; Zips D; Paulsen F; Gepfner-Tuma I; Skardelly M; Tatagiba M; Tabatabai G; Garbe C; Forschner A
    Immunotherapy; 2019 Mar; 11(4):297-309. PubMed ID: 30606066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis.
    Jablonska PA; Muniz T; Ribeiro M; Liu ZA; Ye XY; Devaraja K; Laperriere N; Millar BA; Conrad T; Kongkham P; Butler M; Shultz DB
    J Neurooncol; 2023 Aug; 164(1):199-209. PubMed ID: 37552363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
    Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
    J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.